|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,890.00 GBX | -1.15% |
|
-1.63% | +0.73% |
Business description: AstraZeneca PLC
- product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (5.8%).
Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).
Number of employees: 94,300
Sales by Activity: AstraZeneca PLC
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 2.66TCr | 3.74TCr | 4.44TCr | 4.58TCr | 5.41TCr |
Geographical breakdown of sales: AstraZeneca PLC
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 895.5Cr | 1.2TCr | 1.73TCr | 1.81TCr | 2.18TCr |
China | 534.5Cr | 600.2Cr | 574.3Cr | 587.2Cr | 641.9Cr |
United Kingdom | 174.1Cr | 324.5Cr | 311.7Cr | 336.8Cr | 474Cr |
Other Rest of Europe | 139.1Cr | 194.9Cr | 270.6Cr | 311Cr | 366.3Cr |
Japan | 256.7Cr | 339.5Cr | 398.6Cr | 364Cr | 345.2Cr |
Germany | 94Cr | 148.6Cr | 190.2Cr | 209.9Cr | 252.4Cr |
Other Asia, Africa & Australasia | 153.4Cr | 237.9Cr | 240.6Cr | 204.5Cr | 233.1Cr |
Sweden | 102.6Cr | 232.2Cr | 172.1Cr | 170.4Cr | 229Cr |
Other Americas | 76Cr | 120.3Cr | 117.5Cr | 168.3Cr | 224.6Cr |
France | 65Cr | 92Cr | 110.7Cr | 115.2Cr | 128.3Cr |
Spain | 40Cr | 58Cr | 74Cr | 85Cr | 99Cr |
Italy | 43Cr | 58Cr | 74Cr | 81Cr | 95Cr |
Canada | 60Cr | 77Cr | 116.6Cr | 97Cr | 94Cr |
Australia | 28Cr | 55Cr | 57Cr | 39Cr | 44Cr |
Executive Committee: AstraZeneca PLC
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 01/08/2021 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2023 |
Jeffrey Pott
CMP | Compliance Officer | - | - |
| Chief Tech/Sci/R&D Officer | - | 18/05/2023 |
Composition of the Board of Directors: AstraZeneca PLC
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 27/04/2017 |
Nazneen Rahman
BRD | Director/Board Member | - | 01/06/2017 |
Sherilyn McCoy
BRD | Director/Board Member | 67 | 01/10/2017 |
Shu Kam Mok
BRD | Director/Board Member | 65 | 01/01/2019 |
Michel Demaré
CHM | Chairman | 69 | 27/04/2023 |
Euan Ashley
BRD | Director/Board Member | - | 01/10/2020 |
Diana Layfield
BRD | Director/Board Member | - | 01/11/2020 |
Aradhana Sarin
BRD | Director/Board Member | 52 | 01/08/2021 |
Holdings: AstraZeneca PLC
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,87,50,000 | 75% | 1 880 M $ | |
| 3,50,43,578 | 9.8% | 1 268 M $ | |
| 10,89,23,023 | 24.03% | 898 M $ | |
HBM HOLDINGS LIMITED 8.53% | 7,62,71,762 | 8.53% | 119 M $ |
CELLECTIS S.A. 22.12% | 1,60,00,000 | 22.12% | 79 M $ |
NIOX GROUP PLC 15.82% | 6,60,93,108 | 15.82% | 59 M $ |
| 3,87,329 | 5.8% | 25 M $ | |
INNATE PHARMA 8.12% | 74,85,500 | 8.12% | 14 M $ |
Company details: AstraZeneca PLC
AstraZeneca PLC
Cambridge Biomedical Campus
CB2 0AA, Cambridge
+44 20 3749 5000
http://www.astrazeneca.com
Group companies: AstraZeneca PLC
| Name | Category and Sector |
|---|---|
Astrazeneca Treasury Ltd.
 Astrazeneca Treasury Ltd. Investment Banks/BrokersFinance Operates as a investment holding company through its subsidiaries provides foreign exchange and cash management services |
Investment Banks/Brokers
|
Astrazeneca Treasury Ltd.
Astrazeneca Treasury Ltd. Investment Banks/BrokersFinance Operates as a investment holding company through its subsidiaries provides foreign exchange and cash management services |
Investment Banks/Brokers
|
AstraZeneca India Pvt Ltd.
 AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products |
Pharmaceuticals: Major
|
AstraZeneca India Pvt Ltd.
AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.15% | -1.63% | +28.68% | +21.63% | 29TCr | |
| +0.53% | -2.37% | +43.09% | +194.99% | 93TCr | |
| -0.41% | +6.98% | +48.72% | +28.81% | 53TCr | |
| -1.11% | -2.60% | +24.94% | +43.67% | 38TCr | |
| -0.60% | +1.26% | +29.94% | +17.78% | 37TCr | |
| -0.03% | +1.51% | +29.51% | +36.74% | 28TCr | |
| -1.93% | -1.54% | +11.14% | +0.04% | 27TCr | |
| -2.92% | -0.41% | -31.52% | -21.19% | 27TCr | |
| +0.12% | +1.32% | +21.43% | +24.97% | 18TCr | |
| +3.01% | +3.15% | +36.01% | +49.16% | 15TCr | |
| Average | -0.48% | +0.95% | +24.19% | +39.66% | 36.46TCr | |
| Weighted average by Cap. | -0.45% | +0.62% | +29.28% | +66.50% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
- Company AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition